Mosunetuzumab for systemic lupus erythematosus treatment
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests a new drug called mosunetuzumab in people with systemic lupus erythematosus (SLE), a disease where the immune system attacks the body's own tissues. The drug is designed to help control the immune response and reduce lupus symptoms, including kidney involvement if present.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with SLE for at least 6 months before screening
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study
- You must not have an active infection (except nail fungus) or serious infection history
- You cannot have a history of tuberculosis, certain cancers in the past 5 years, or PML (a rare brain infection)
- You must not have received other experimental therapies in the past 30 days or certain other recent treatments (like live vaccines in the past 28 days)
- You cannot have severe or unstable brain/nervous system involvement related to lupus or high bleeding risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called obinutuzumab for people with lupus kidney disease (specifically class V membranous nephropathy) who have protein in their urine. The goal is to see if this treatment can reduce protein leakage and preserve kidney function.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This study tests an experimental injection called ZM001 for people with severe lupus that hasn't improved with standard treatments. The goal is to see if this new therapy can help control the disease.
This trial tests a new medicine called O-triple for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if it can control the disease and help protect kidney function.
This study tests a new antibody drug called mosunetuzumab in patients with chronic lymphocytic leukemia (CLL) who have already tried other treatments and still have detectable leukemia cells in their bone marrow. The drug is designed to work in a way that might help your immune system fight the remaining cancer cells.
This trial tests a new drug called mosunetuzumab for people with a type of slow-growing lymphoma (extranodal marginal zone lymphoma) that has not been treated before. The goal is to see if the drug helps shrink the lymphoma and control the disease.
Hear when a new Lupus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.